Table 3.
Prediction factors for progression in patients with small cell lung cancer limited stage assessed by Cox proportional hazard model
| Parameters | Hazard ratio | 95% CI | P value |
|---|---|---|---|
| Univariate analysis | |||
| Age | 1.004 | 0.966-1.044 | 0.825 |
| Gender, male | 1.101 | 0.466-2.603 | 0.826 |
| Smoking (Ever smoker) | 0.710 | 0.279-1.806 | 0.472 |
| ECOG performance | 1.327 | 0.658-1.327 | 0.430 |
| Paraneoplastic syndrome | 0.044 | 0.000-6.186 | 0.215 |
| LDH value | 1.003 | 1.000-1.005 | 0.020 |
| TNM stage | 1.615 | 0.388-6.725 | 0.804 |
| Thoracic radiotherapy | 1.491 | 0.534-4.164 | 0.446 |
| Prophylactic cranial irradiation | 0.603 | 0.321-1.133 | 0.116 |
| Concurrent chemoradiation therapy | 0.897 | 0.466-1.727 | 0.745 |
| NQO1 polymorphism | 0.670 | 0.299-1.502 | 0.331 |
| Positive p53 | 0.675 | 0.370-1.231 | 0.200 |
| Positive SOD2 | 0.866 | 0.475-1.578 | 0.638 |
| Positive PARP1 | 0.500 | 0.271-0.925 | 0.027 |
| Multivariate analysis | |||
| Age | 1.001 | 0.964-1.039 | 0.964 |
| ECOG performance | 1.163 | 0.566-2.391 | 0.681 |
| Prophylactic cranial irradiation | 0.611 | 0.317-1.178 | 0.141 |
| Positive PARP1 | 0.494 | 0.267-0.913 | 0.025 |